Distribution of contezolid in different tissues of mice and human patients infected with Mycobacterium abscessus

Qi Li,Yujin Wang,Qingdong Zhu,Yanrong Lin,Naihui Chu,Yu Lu,Wenjuan Nie

DOI: https://doi.org/10.1101/2024.12.03.626643

2024-12-03

Abstract:Background: Linezolid (LZD), while effective against Mycobacterium abscessus (MAB), can cause myelosuppression and peripheral neuropathy. Contezolid (CZD) shares a similar antimicrobial profile with improved safety, but biodistribution data remain limited. This study evaluated CZD’s biodistribution in MAB-infected mice and humans and its therapeutic potential across infection sites. Methods: MICs of CZD and LZD against 32 clinical MAB isolates and three reference strains were determined. In MAB-infected mice, drug concentrations were quantified in plasma and pulmonary and cerebral tissues at 2, 4, and 8 hours post-administration. In MAB-infected patients, CZD concentrations in bone, plasma, and cerebrospinal fluid were measured at multiple time points and MAB counts in sputum cultures were assessed daily over 14 days. Results: Respective MIC and MIC values were 8 and 32 μg/mL (LZD) and 16 and 32 μg/mL (CZD). Pharmacokinetic CZD and LZD level comparisons revealed peak CZD plasma levels within 2 hours, higher systemic CZD levels, comparable pulmonary tissue concentrations, and slightly lower CZD cerebral tissue penetration. In patients, CZD levels in ankle joint effusion samples reached 2.0885 μg/mL at 6 hours, peaking in the posterior malleolus. Plasma CZD concentrations peaked at 8.2349 μg/mL at 3 hours and dropped to 6.1065 μg/mL by 6 hours, while CSF levels were 0.9295 and 0.792 μg/mL at 3 and 6 hours, respectively. Sputum bacterial burden decreased rapidly within 24 hours of CZD treatment, with near-complete clearance by day 4. Conclusion: CZD and LZD exhibit comparable tissue distribution but different site-specific penetration, supporting their potential for treating diverse MAB infections.

Microbiology